Is PPHM a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

2,626 people get PPHM articles and Market Currents by email alert.

Get email alerts on PPHM »

HEADLINES:

Peregrine Pharmaceuticals' Immunotherapy Bavituximab to Be Highlighted in Three Clinical Data Presentations at 2013 ASCO Annual Meeting

Marketwire (Thu, 8:30AM)
Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential
Life Sciences Report • Fri, May 3 • 3 Comments
Peregrine Announces Completion of Patient Enrollment in Breast Cancer Clinical Trial for Bavituximab

Marketwire (Apr 29, 2013)
Threshold: My Biotech Pick Of The Year
Equity Options Guru • Tue, Apr 23 • 14 Comments
Data Presented at AACR Annual Meeting Support Targeted Immune Reactivation Mechanism and Potential of Peregrine's Bavituximab in Solid Tumor Therapy

Marketwire (Apr 10, 2013)
Peregrine Announces Three Abstracts Accepted for Presentation at AACR 2013 Annual Meeting

Marketwire (Apr 1, 2013)
Follow The Crashing Biotechs: 4 Stocks Fresh From A Fall
Craig Keolanui • Wed, Mar 20 • 4 Comments
Peregrine Releases Earnings, But The Situation Remains The Same
Brian L. Wilson • Wed, Mar 13 • 5 Comments
Peregrine Pharmaceuticals Management Discusses Q3 2013 Results - Earnings Call Transcript
Tue, Mar 12
Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2013 Financial Results and Recent Developments

Marketwire (Mar 12, 2013)
Peregrine's Bavituximab Future Looks Bleak
Chimera Research Group • Tue, Mar 12 • 17 Comments
Why These 4 Biotechs Could Be Next In Line To See Their Share Prices Rise
Vineet Dutta • Fri, Mar 8 • 8 Comments
George Zavoico: Biotech Stocks That Deserve A Closer Look
Life Sciences Report • Fri, Mar 8 • 1 Comment
2 Biotech Superstars For 2013
Equity Options Guru • Tue, Mar 5 • 30 Comments
Peregrine to Report Third Quarter Fiscal Year 2013 Financial Results After Market Close on March 12, 2013

Marketwire (Mar 5, 2013)
Peregrine Announces Participation at Upcoming Investor Conferences

Marketwire (Feb 26, 2013)
Peregrine Pharmaceuticals' Bavituximab: It's Time To Throw In The Towel
Robert Schwartz • Tue, Feb 26 • 53 Comments
A Biotech Winner For 2013
Equity Options Guru • Thu, Feb 21 • 15 Comments
VIX - Options Volatility And Market Sonar: Tuesday Recap
Erick McKitterick • Tue, Feb 19 • 11 Comments
Peregrine Pharmaceuticals Updates Top-Line Data From Phase II Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer

Marketwire (Feb 19, 2013)

To learn more about Seeking Alpha Pro, click here.

Peregrine Releases Earnings, But The Situation Remains The Same
Brian L. Wilson • Wed, Mar 13 • 5 Comments
Peregrine's Bavituximab Future Looks Bleak
Chimera Research Group • Tue, Mar 12 • 17 Comments
Peregrine Pharmaceuticals' Bavituximab: It's Time To Throw In The Towel
Robert Schwartz • Tue, Feb 26 • 53 Comments
Peregrine Recovers As Phase II Trial Is Salvaged
Brian L. Wilson • Wed, Jan 9 • 13 Comments
Now You See It, Now You Don't: Peregrine's Bavi Might Work After All
EP Vantage • Tue, Jan 8 • 14 Comments
Peregrine Pharmaceutical's Big Jump
WM Analyst • Mon, Jan 7 • 3 Comments
Peregrine Pharmaceuticals Beats Earnings Estimates
WM Analyst • Tue, Dec 11, 2012 • 3 Comments
Recent Catalysts For Peregrine Pharmaceuticals
WM Analyst • Fri, Dec 7, 2012 • 2 Comments
Assessing Peregrine And Seeking Upside In The Space
The Swiss Trader • Mon, Oct 1, 2012 • 11 Comments
Little Value In Peregrine Pharmaceuticals
Chimera Research Group • Thu, Sep 27, 2012 • 2 Comments
More Downside Expected In Peregrine Pharmaceuticals
Chimera Research Group • Mon, Aug 27, 2012 • 71 Comments
Peregrine: Bavi Results Are Overhyped And Inconclusive
Apsara Biotechnology Research • Wed, Aug 22, 2012 • 94 Comments
Several Catalysts Are Near For Peregrine Pharmaceuticals
Adam Gefvert • Wed, Aug 15, 2012 • 53 Comments
Peregrine's Lung Cancer Drug Has Promising Trial
Adam Gefvert • Wed, Dec 7, 2011 • 10 Comments
Trial News Make Peregrine Pharmaceuticals Worth Watching
M. E. Garza • Tue, Jan 11, 2011 • 7 Comments
Peregrine Reports Positive Interim Survival Data From Brain Cancer Drug Study
Proactive Investor • Tue, Oct 19, 2010 • 3 Comments
Peregrine Pharmaceuticals: Good Long Term Potential
VFC's Stock House • Wed, Jun 16, 2010 • 6 Comments
Peregrine: Continuing to Accumulate on Any Dips
VFC's Stock House • Tue, Oct 20, 2009 • 5 Comments
Continuing to Accumulate Peregrine Pharma at Current Levels
VFC's Stock House • Thu, Oct 8, 2009 • 7 Comments

Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential
Life Sciences Report • Fri, May 3 • 3 Comments
Threshold: My Biotech Pick Of The Year
Equity Options Guru • Tue, Apr 23 • 14 Comments
Follow The Crashing Biotechs: 4 Stocks Fresh From A Fall
Craig Keolanui • Wed, Mar 20 • 4 Comments
Why These 4 Biotechs Could Be Next In Line To See Their Share Prices Rise
Vineet Dutta • Fri, Mar 8 • 8 Comments
George Zavoico: Biotech Stocks That Deserve A Closer Look
Life Sciences Report • Fri, Mar 8 • 1 Comment
2 Biotech Superstars For 2013
Equity Options Guru • Tue, Mar 5 • 30 Comments
A Biotech Winner For 2013
Equity Options Guru • Thu, Feb 21 • 15 Comments
VIX - Options Volatility And Market Sonar: Tuesday Recap
Erick McKitterick • Tue, Feb 19 • 11 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Thu, Feb 14 • 1 Comment
Response Genetics' Competitors: Who To Watch, Who To Worry About
Bay Area Biotech • Fri, Feb 8 • 7 Comments
Speculative Biotech Stocks That Could Bounce
BuySellShort • Thu, Feb 7 • 23 Comments
How Individuals Can Gain An Advantage Over Institutional Investors
Robert Mann • Tue, Jan 29 • 5 Comments
Tuesday's Small Cap Biopharma Investment And Catalyst Trade List
Scott Matusow • Tue, Jan 8 • 5 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Tue, Jan 8 • 1 Comment
Biotech Weekly Recap: The Market Holds While Biotech Crumbles
Brian L. Wilson • Sun, Dec 9, 2012 • 6 Comments
Hedge Funds Are Bullish About These Stocks
Insider Monkey • Thu, Dec 6, 2012 • 4 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Mon, Dec 3, 2012 • 1 Comment
Biotech Weekly Recap: Loads Of Bullishness, 2 Giant Rallies, And Selling
Brian L. Wilson • Sun, Dec 2, 2012 • 19 Comments
4 Speculative Investments You Might Want To Consider
Amy Baldwin • Mon, Nov 19, 2012 • 12 Comments
5 Big Time Biotech Movers On Wednesday
Amy Baldwin • Thu, Oct 18, 2012 • 5 Comments

Peregrine Pharmaceuticals Management Discusses Q3 2013 Results - Earnings Call Transcript
Tue, Mar 12
Peregrine Pharmaceuticals' CEO Discusses F2Q 2013 Results - Earnings Call Transcript
Mon, Dec 10, 2012
Peregrine Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Mon, Sep 10, 2012
Peregrine Pharmaceuticals Management Discusses Q4 2012 Results - Earnings Call Transcript
Mon, Jul 16, 2012 • 1 Comment
Peregrine Pharmaceuticals' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Fri, Mar 9, 2012
Peregrine Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Mon, Dec 12, 2011 • 1 Comment
Peregrine Pharmaceuticals Inc. Presents at Lazard Capital Markets 8th Annual Healthcare Conference, Nov-15-2011 11:30 AM
Tue, Nov 15, 2011
Peregrine Pharmaceuticals' CEO Discusses Q1 2012 Results - Earnings Call Transcript
Fri, Sep 9, 2011
Peregrine Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript
Thu, Jul 14, 2011
Peregrine Pharmaceuticals' CEO Discusses Q3 2011 Results - Earnings Call Transcript
Fri, Mar 11, 2011 • 2 Comments
Peregrine Pharmaceuticals CEO Discusses F2Q2011 Results – Earnings Call Transcript
Thu, Dec 9, 2010
Peregrine Pharmaceuticals CEO Discusses F1Q2011 Results - Earnings Call Transcript
Thu, Sep 9, 2010
Peregrine Pharmaceuticals, Inc. F4Q10 (Qtr End 04/30/10) Earnings Call Transcript
Wed, Jul 14, 2010
Peregrine Pharmaceuticals, Inc. F3Q10 (Qtr End 01/31/10) Earnings Call Transcript
Thu, Mar 11, 2010
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
Thu, Dec 10, 2009 • 1 Comment
Peregrine Pharmaceuticals Inc., F1Q10 (Qtr End 07/31/09) Earnings Call Transcript
Thu, Sep 3, 2009 • 1 Comment
Peregrine Pharmaceuticals, Inc. F4Q09 (Qtr End 04/30/09) Earnings Call Transcript
Tue, Jul 14, 2009 • 1 Comment
Peregrine Pharmaceuticals F2Q09 (Qtr End 10/31//08) Earnings Call Transcript
Wed, Dec 10, 2008
Peregrine Pharmaceuticals, Inc. F1Q09 (Qtr End 07/31/08) Earnings Call Transcript
Tue, Sep 9, 2008
Peregrine Pharmaceuticals, Inc. F4Q08 (Yr End 04/30/08) Earnings Call Transcript
Mon, Jul 14, 2008

Peregrine Pharmaceuticals' Immunotherapy Bavituximab to Be Highlighted in Three Clinical Data Presentations at 2013 ASCO Annual Meeting

Marketwire (Thu, 8:30AM)
Peregrine Announces Completion of Patient Enrollment in Breast Cancer Clinical Trial for Bavituximab

Marketwire (Apr 29, 2013)
Data Presented at AACR Annual Meeting Support Targeted Immune Reactivation Mechanism and Potential of Peregrine's Bavituximab in Solid Tumor Therapy

Marketwire (Apr 10, 2013)
Peregrine Announces Three Abstracts Accepted for Presentation at AACR 2013 Annual Meeting

Marketwire (Apr 1, 2013)
After-Hours Buzz: BA, URBN & More

at CNBC.com (Mar 12, 2013)
Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2013 Financial Results and Recent Developments

Marketwire (Mar 12, 2013)
After-Hours Buzz: PAY, NTRI, PLL & More

at CNBC.com (Mar 5, 2013)
Peregrine to Report Third Quarter Fiscal Year 2013 Financial Results After Market Close on March 12, 2013

Marketwire (Mar 5, 2013)
Peregrine Announces Participation at Upcoming Investor Conferences

Marketwire (Feb 26, 2013)
Peregrine Pharmaceuticals Updates Top-Line Data From Phase II Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer

Marketwire (Feb 19, 2013)
Peregrine Pharmaceuticals Announces Results From Phase II Clinical Trial of Bavituximab in Stage IV Pancreatic Cancer

Marketwire (Feb 13, 2013)
Peregrine Pharmaceuticals Provides Update on the Internal Review of Its Phase II Second-Line Non-Small Cell Lung Cancer Trial

Marketwire (Jan 7, 2013)
Peregrine Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement

Marketwire (Dec 11, 2012)
Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2013 Financial Results and Recent Developments

Marketwire (Dec 10, 2012)
Peregrine Pharmaceuticals Announces Significant Progress in Advancing Its Cotara Program Into a Pivotal Phase III Trial

Marketwire (Dec 5, 2012)
Peregrine to Report Second Quarter Fiscal Year 2013 Financial Results After Market Close on December 10, 2012

Marketwire (Dec 3, 2012)
Peregrine Pharmaceuticals Announces Receipt of Notice From NASDAQ

Marketwire (Nov 14, 2012)
New Data Support Ability of PS-Targeting Antibodies to Specifically Target Tumors and Stimulate Cancer-Fighting Immune Responses

Marketwire (Oct 31, 2012)
Peregrine Pharmaceuticals Provides Update on Corporate Activities

Marketwire (Oct 17, 2012)
Peregrine Pharmaceuticals Announces New Location of Annual Meeting of Stockholders

Marketwire (Sep 27, 2012)

PPHM vs. ETF Alternatives

Company Description

We are a clinical stage biopharmaceutical company that manufactures and develops monoclonal antibodies for the treatment of cancer and serious viral infections. We are advancing three separate clinical programs with our novel compounds bavituximab and Cotara® that are the first clinical... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Monday, April 29, 9:27 AM Peregrine Pharmaceuticals (PPHM) says it has completed enrollment in a Phase I trial for bavituximab to evaluate the safety, feasibility, and tolerability of the drug in combination with the chemotherapeutic agent paclitaxel for the treatment of breast cancer. Shares +7% premarket. (PR) Comment! [Healthcare, On the Move]
Monday, April 29, 9:15 AM Premarket gainers: SINA +22%. CPTS +20%. PPHM +8%. NIHD +8%. THC +7%. PBR +6%. HCA +9%. HMA +5%. MCO +5%. RDN +5%.
Losers: NTE -27%. GORO -9%. NBG -8%. RVLT -5%. Comment! [On the Move]
Wednesday, April 10, 9:10 AM Premarket gainers: ADTN +8%. PPHM +6%. NJ +6%.
Losers: TITN -18%. HMA -14%. SGYP -13%. RLGY -6%. GRA -5%. Comment! [On the Move]
Wednesday, April 10, 9:01 AM Peregrine Pharmaceuticals (PPHM +6%) presents pre-clinical data at the annual meeting of the American Association for Cancer Research showing the potential of the company's Bavituximab drug for fighting lung cancer, and of other molecules that the firm's developing. Peregrine intends to start Phase III trials of Bavituximab later this year. (PR) Comment! [Healthcare]
Wednesday, March 20, 12:45 PM Midday top 10 gainers: OMPI +28%. AFFY +18%. MTSL +13%. NPD +12%. CHYR + 12%. GEVO +12%. WSM +11%. BIOF +10%. AIR +9%. PPHM +8%.
Midday top 10 losers: ATOS -18%. LIVE -15%. MXWL -15%. CHKR -14%. ECT -12%. CIG -13%. SGOC -12%. FFEX -11%. ABCD -11%. OTIV -9%. Comment! [On the Move]
Wednesday, March 13, 9:10 AM Premarket gainers: BGMD +15%. SUMR +10%. PPHM +5%.
Losers: SPPI -36%. VELT -32%. ASMI -13%. EXPR -13%. TEU -10%. DOLE -7%. WFR -6%. Comment! [On the Move]
Tuesday, March 12, 4:18 PM More on Peregrine Pharmaceuticals (PPHM): Q3 beats on all counts as total revenue nearly doubles. The company cites greater contract manufacturing revenue generated by Avid Bioservices, it's wholly-owned contract manufacturing subsidiary, which generated contract manufacturing revenue of $6.9M for the third quarter of FY 2013, compared to $3.2M for the prior year. For the remainder of FY13, it expects contract manufacturing revenue to be at least $20M. Shares +7.6% AH. Comment! [Healthcare, Earnings, On the Move]
Tuesday, March 12, 4:02 PM Peregrine Pharmaceuticals (PPHM): FQ3 EPS of -$0.04 beats by $0.03. Revenue of $7.03M beats by $3.13M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, March 12, 12:10 AM Notable earnings after Tuesday’s close: DOLE, GERN, HRZN, IRET, KTOS, PPHM, VELT Comment! [Earnings]
Monday, March 11, 5:35 PM Notable earnings after Tuesday’s close: DOLE, GERN, HRZN, IRET, KTOS, PPHM, VELT 2 Comments [Earnings]
Friday, March 8, 12:13 PM Shares of Peregrine Pharmaceuticals (PPHM +15%) are surging on no specific news today. Piper initiated the shares with an Overweight earlier this week - which gave the stock a +9% pop - citing optimism over its two novel cancer drug candidates, bavituximab and Cotara. Further data on overall survival rates for bavituximab are expected to be presented at an upcoming scientific meeting later this year. 2 Comments [Healthcare, On the Move]
Wednesday, March 6, 10:50 AM Peregrine Pharmaceuticals (PPHM +5.4%) gains this morning after Piper Jaffray initiated the shares with an Overweight rating and $2.50 price target. Piper says PPHM is advancing two cancer drug candidates that, combined with its hybrid business model, present an attractive risk-reward opportunity. Additionally, the negative press over its lead drug candidate bavituximab has created a potential entry point to pick up the shares at a discount. Comment! [Healthcare, On the Move]
Wednesday, March 6, 9:10 AM Premarket gainers: PRAN +13%. PBR +12%. CYTX +9%. PPHM +8%. GEVO +8%. MTG +8%. TSL +8%. HNR +7%. BIG +7%.PBR.A +6%. PAY +5%. WPRT +5%.
Losers: AVAV -25%. TFM -11%. AEO -9%. SOHU -8%. QIHU -5%. NBG -5%. Comment! [On the Move]
Wednesday, February 27, 11:12 AM Peregrine Pharmaceuticals (PPHM +8.7%) regains some yesterday's decline after the company was featured in a pessimistic article in Seeking Alpha. The stock actually began its fall on Monday, but was exacerbated yesterday by the SA piece by contributor Robert Schwartz, who noted that PPHM's lead drug candidate, bavituximab, has had twelve Phase-I/-II studies and treated 613 cancer patients but has yet to observe a statistically significant improvement over a contemporary standard-of-care. Schwartz thinks its time to throw in the towel. 5 Comments [Healthcare, On the Move]
Tuesday, February 19, 10:51 AM For a second session, Peregrine Pharmaceuticals (PPHM -3.8%) trades up in the premarket only to give back the early gains plus more, as the company announces encouraging but not stellar results in its Phase II clinical update of bavituximab for the treatment of stage IV pancreatic cancer. 3 Comments [Healthcare, On the Move]
Wednesday, February 13, 12:35 PM Shares of Peregrine Pharmaceuticals (PPHM -2%) take a wild swing lower after opening solidly in the green this morning on the back of news that its bavituximab treatment performed well in Phase II trials. Comment! [Healthcare, On the Move]

TipRanks
Worst recommendation of 2013! 80% loss $CLSN $PPHM http://seekingalpha.com/p/12sbt
Apr 30, 2:01 PM
Reply (5)

• !Report Abuse
View all 5 replies
TipRanks: Perkins - thanks for the kind words! let us know what cool features should we add.
May 1, 12:15 AM
• !Report Abuse
353276: $CLSN beats the street by .04
May 9, 9:15 AM
• !Report Abuse
Add a reply...

140 characters

rph1225
$PPHM FBI waiting for AF Crutcher write away boys
Mar 25, 10:41 AM
Reply (3)

• !Report Abuse
View all 3 replies
rph1225: AF Dew Diligence The street .com is going to run PPHM next couple BIG PRs take profits crew will short just as hard again if stock goes high
Apr 20, 1:43 PM
• !Report Abuse
rph1225: PPHM is in play they will pump run it like DNDN HGSI then short take profits is my word of advice!
Apr 20, 1:44 PM
• !Report Abuse
Add a reply...

140 characters

TruffelPig
$PPHM - was about time the Chimera Research came with another bashing just on the day of earning. Expect AF to show up shortly.
Mar 12, 8:08 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

TruffelPig
$PPHM - Piper Jaffray starts it with OVERWEIGHT and PT $2.5 - that is ca. 100% upside. Will we see 2.5 tomorrow?
Mar 5, 9:08 PM
Reply (7)

• !Report Abuse
View all 7 replies
TruffelPig: http://bit.ly/W3P9Ea
Mar 5, 9:26 PM
• !Report Abuse
TruffelPig: the 2.5 was kind off referring to recent insanity....I wasn't serious there. But who knows.....
Mar 5, 9:28 PM
• !Report Abuse
Add a reply...

140 characters

wmuraga
$PPHM...only way is up on this one IMHO.
Feb 21, 1:27 AM
Reply (1)

• !Report Abuse
View all 1 replies
DaLatin: Agree, the one eroneus test allowed entry under a buck. I got in as the pipeling seems solid going out.
Feb 21, 5:40 AM
• !Report Abuse
Add a reply...

140 characters

slinzer
$PPHM Does anyone know why this stock is still being shorted when they are releasing good news??
Feb 19, 11:27 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

TruffelPig
$PPHM update on phase II NSLC trial good news. MOS extended to >11 month from 7 month for control.
Feb 19, 8:40 AM
Reply (1)

• !Report Abuse
View all 1 replies
TruffelPig: Bought some on that one. Good price still PM.
Feb 19, 8:41 AM
• !Report Abuse
Add a reply...

140 characters

TruffelPig
Trivia: both $CLF and $PPHM lost 19.9% of their value today.
Feb 13, 8:23 PM
Reply (5)

• !Report Abuse
View all 5 replies
TruffelPig: Still a bit too high - lol.
Feb 13, 9:14 PM
• !Report Abuse
REIT: hehe anything can happen, seen much better companies dive under and come out
Feb 13, 10:17 PM
• !Report Abuse
Add a reply...

140 characters

Perkins Cove
$PPHM, now up 75%. Sorry for the delayed posts. http://seekingalpha.com/s/alh8z
Jan 7, 1:13 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Perkins Cove
$PPHM now up +80% (Perkins Cove posts are being delayed)...http://seekingalpha.com/s/alh8z
Jan 7, 11:15 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

TipRanks
Worst recommendation of 2013! 80% loss $CLSN $PPHM http://seekingalpha.com/p/12sbt
Apr 30, 2:01 PM
Reply (5)

• !Report Abuse
View all 5 replies
TipRanks: Perkins - thanks for the kind words! let us know what cool features should we add.
May 1, 12:15 AM
• !Report Abuse
353276: $CLSN beats the street by .04
May 9, 9:15 AM
• !Report Abuse
Add a reply...

140 characters

rph1225
$PPHM FBI waiting for AF Crutcher write away boys
Mar 25, 10:41 AM
Reply (3)

• !Report Abuse
View all 3 replies
rph1225: AF Dew Diligence The street .com is going to run PPHM next couple BIG PRs take profits crew will short just as hard again if stock goes high
Apr 20, 1:43 PM
• !Report Abuse
rph1225: PPHM is in play they will pump run it like DNDN HGSI then short take profits is my word of advice!
Apr 20, 1:44 PM
• !Report Abuse
Add a reply...

140 characters

TruffelPig
$PPHM - Piper Jaffray starts it with OVERWEIGHT and PT $2.5 - that is ca. 100% upside. Will we see 2.5 tomorrow?
Mar 5, 9:08 PM
Reply (7)

• !Report Abuse
View all 7 replies
TruffelPig: http://bit.ly/W3P9Ea
Mar 5, 9:26 PM
• !Report Abuse
TruffelPig: the 2.5 was kind off referring to recent insanity....I wasn't serious there. But who knows.....
Mar 5, 9:28 PM
• !Report Abuse
Add a reply...

140 characters

wmuraga
$PPHM...only way is up on this one IMHO.
Feb 21, 1:27 AM
Reply (1)

• !Report Abuse
View all 1 replies
DaLatin: Agree, the one eroneus test allowed entry under a buck. I got in as the pipeling seems solid going out.
Feb 21, 5:40 AM
• !Report Abuse
Add a reply...

140 characters

TruffelPig
$PPHM update on phase II NSLC trial good news. MOS extended to >11 month from 7 month for control.
Feb 19, 8:40 AM
Reply (1)

• !Report Abuse
View all 1 replies
TruffelPig: Bought some on that one. Good price still PM.
Feb 19, 8:41 AM
• !Report Abuse
Add a reply...

140 characters

TruffelPig
Trivia: both $CLF and $PPHM lost 19.9% of their value today.
Feb 13, 8:23 PM
Reply (5)

• !Report Abuse
View all 5 replies
TruffelPig: Still a bit too high - lol.
Feb 13, 9:14 PM
• !Report Abuse
REIT: hehe anything can happen, seen much better companies dive under and come out
Feb 13, 10:17 PM
• !Report Abuse
Add a reply...

140 characters

Perkins Cove
$PPHM up 28% pre mkt on Roth upgrade to buy. Nice! Be safe out there.....
Jan 7, 9:10 AM
Reply (3)

• !Report Abuse
View all 3 replies
TruffelPig: Roth is manipulating this like crazy. No news......
Jan 7, 1:41 PM
• !Report Abuse
TruffelPig: I am not a buyer - made my money and won't give it back.
Jan 7, 1:41 PM
• !Report Abuse
Add a reply...

140 characters

TruffelPig
PPHM coming back - up 37% PM.......crazy crazy. Just observing. Made my money and won't give it back.
10/17/12
Reply (1)

• !Report Abuse
View all 1 replies
Ashraf Eassa: It's just your typical micro-cap pumping and dumping. Nothing to see.
10/17/12
• !Report Abuse
Add a reply...

140 characters

Noreika
Anyone looking to knife catch? $OCZ, $PPHM Thoughts?
10/12/12
Reply (2)

• !Report Abuse
View all 2 replies
Austin Craig: catching ocz is like catching a running chainsaw. Your either catching the running chain or getting hit via the motor.
10/13/12
• !Report Abuse
Noreika: That bad, huh? Yeah, I'm hesitant..
10/13/12
• !Report Abuse
Add a reply...

140 characters

bigdividendsonly
PPHM 82 cents.. Under a buck was re-entry plan
10/2/12
Reply (5)

• !Report Abuse
View all 5 replies
Perkins Cove: True Fort. Today's adrenaline rush....ARQL (low in pre mkt @ 1.81)
10/2/12
• !Report Abuse
TruffelPig: Rialto, the ARQL would have been fantastic........
10/13/12
• !Report Abuse
Add a reply...

140 characters

das756
thinking of adding to HEK,also PPHM when it goes back down.
9/27/12
Reply (2)

• !Report Abuse
View all 2 replies
Model629: time to stop thinking and start adding...
9/28/12
• !Report Abuse
Model629: $4.16...
9/28/12
• !Report Abuse
Add a reply...

140 characters

bigdividendsonly
NYMT added at 7.04 with PPHM swing gains
9/27/12
Reply (1)

• !Report Abuse
View all 1 replies
sector: Also long NYMT and ARR
9/28/12
• !Report Abuse
Add a reply...

140 characters

bigdividendsonly
PPHM stop hit 1.28 from 1.29 stop.. 6 cent loss on 1.35 buy and 11 gain on 1.17 buy. O/k and under 1 an I go back
9/27/12
Reply (3)

• !Report Abuse
View all 3 replies
bigdividendsonly: 1.11 and taking a 14 cent gain ! Using gain to add NYMT at 7.04
9/27/12
• !Report Abuse
bigdividendsonly: Was worth it ! The gain added 1350 NYMT shares from 19 cent gains on 50K block swings.Pool grew steady all year +cash boomed 3 solid digits
9/28/12
• !Report Abuse
Add a reply...

140 characters

Perkins Cove
PPHM as low as 1.15 pre mkt so far. If you play, don't bet the farm.
9/27/12
Reply (2)

• !Report Abuse
View all 2 replies
Perkins Cove: Roth Capital says neutral, PT = $.70
9/27/12
• !Report Abuse
Perkins Cove: 8:10am, Avid Biosciences (PPHM subsidiary) to provide services (re HIV vaccine) to Advanced Bioscience Lab. (Breifing.com)
9/27/12
• !Report Abuse
Add a reply...

140 characters

iadops40
I feel bad for the PPHM longs after more bad news today after hours...knife catchers getting a learning lesson here
9/26/12
Reply (12)

• !Report Abuse
View all 12 replies
chuckholladay: Yes paid the 15m loan in full and has enough capital to fund operations thru April 2013 according to Reuter's report posted on FinViz
9/26/12
• !Report Abuse
iadops40: enough capital to last thru Q4 (Feb or April), but that would not be enough time to redo their phase II trials.
9/26/12
• !Report Abuse
Add a reply...

140 characters

PPHM Peregrine Pharmaceuticals Inc.

PPHM

Peregrine Pharmaceuticals Inc.